Compare Enveric Biosciences Inc (ENVB) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Lululemon Athletica Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Lululemon Athletica Inc trades at $94.5 (market cap $10.27B). The key difference: Lululemon Athletica Inc is far larger — about 1510.3× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 4,392,324). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Lululemon Athletica Inc for 105 Days on average.
| ENVB | LULU | |
|---|---|---|
Market Cap | $6.80M | $10.27B |
Volume | 64,867 | 4,392,324 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $215.88 |
52-Week Low | $1.27 | $91.88 |
Typical Hold Time | 14 Days | 105 Days |
Enterprise Value | -$1.49M | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% today, with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and ROA at -193.53%, though it has consistently beaten EPS estimates in recent quarters. Recent positive developments include new patent allowances and preclinical data supporting its non-hallucinogenic drug candidates.
The outlook remains speculative given the lack of revenue and negative cash flow from operations, offset by strong analyst buy ratings (75%). Key risks include clinical trial outcomes and funding needs, while catalysts hinge on regulatory progress and successful drug development in the competitive biotech space.
Lululemon (LULU) stock trades at $92.68, down 54% year-to-date and near its 52-week low. The technical outlook is bearish, while fundamentals show strong profitability with a 56.11% gross margin and a low P/E of 7.63. Recent earnings beats are overshadowed by a revenue decline and multiple securities fraud investigations announced in late September 2026.
The stock presents a value opportunity based on depressed valuation multiples, but significant risks exist from legal scrutiny, competitive pressures, and weakening growth. Analyst consensus is a 'Hold' with a $97.67 price target, indicating cautious optimism amid high uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
